SAN DIEGO, April 2, 2019 /PRNewswire/ -- MEI Pharma,
Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on
advancing new therapies for cancer, today announced that
Daniel P. Gold, Ph.D., president and
chief executive officer, will present at the 18th Annual
Needham Healthcare Conference on Tuesday,
April 9, 2019 at 10:40 a.m.
ET. The conference will take place April 9-10,
in New York, N.Y.
A live audio webcast of the event can be accessed on the Events
& Presentations page of the Investors section of MEI Pharma's
website at http://www.meipharma.com.
An archived replay of the webcast will be available on MEI
Pharma's website for at least 30 days after the live event
concludes.
About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a
late-stage pharmaceutical company focused on developing potential
new therapies for cancer. Our portfolio of drug candidates contains
four clinical-stage assets, including one candidate in an ongoing
global registration trial and another candidate in a Phase 2
clinical trial which may support an accelerated approval marketing
application with the U.S. Food and Drug Administration. Each of our
pipeline candidates leverages a different mechanism of action with
the objective of developing therapeutic options that are: (1)
differentiated, (2) address unmet medical needs and (3) deliver
improved benefit to patients either as standalone treatments or in
combination with other therapeutic options. For more information,
please visit www.meipharma.com.
Under U.S. law, a new drug cannot be marketed until it has
been investigated in clinical studies and approved by the FDA as
being safe and effective for the intended use. Statements included
in this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements,
which are based on management's current expectations and are
subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product
candidates; costs and delays in the development and/or FDA
approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in
clinical trial results; our inability to maintain or enter into,
and the risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights to third
party patents and intellectual property to operate our business;
our inability to operate our business without infringing the
patents and proprietary rights of others; general economic
conditions; the failure of any products to gain market acceptance;
our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events. We do not intend to update any of
these factors or to publicly announce the results of any revisions
to these forward-looking statements.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/mei-pharma-to-present-at-the-18th-annual-needham-healthcare-conference-300820753.html
SOURCE MEI Pharma, Inc.